NEVO trial. Since the trial was not powered for clinical endpoints it is hard to get too excited although it does show promise to continue with the program. It also just as most any trial these days hammers yet another nail in the Taxus coffin. I saw the MDT Resolute stent had a fairly good showing VS Xience. I think BSX needs to yell UNCLE as far as Taxus is concerned it is being beaten like a red headed step child! LMAO
Market Data 
Markets 
AI
